A comparison of levonorgestrel implants with depo-medroxyprogesterone acetate injections for contraception.
D000569:Americas; D001695:Biology; D001943:Breast Neoplasms; D002170:Canada; D003267:Contraception; D003268:Contraception Behavior; D003270:Contraceptive Agents; D003271:Contraceptive Agents, Female; D019049:Developed Countries; D004194:Disease; D005193:Family Planning Services; D007267:Injections; D016912:Levonorgestrel; D017258:Medroxyprogesterone Acetate; D008599:Menstruation Disturbances; D008660:Metabolism; D009369:Neoplasms; D009656:North America; D010342:Patient Acceptance of Health Care; D010827:Physiology; D012106:Research
D003270:Contraceptive Agents; D003271:Contraceptive Agents, Female; D016912:Levonorgestrel; D017258:Medroxyprogesterone Acetate
Americas; Biology; Breast Cancer; Canada; Cancer; Clinical Research; Comparative Studies; Contraception; Contraception Termination; Contraceptive Agents, Female--side effects; Contraceptive Agents, Progestin--side effects; Contraceptive Agents--side effects; Contraceptive Implants--side effects; Contraceptive Methods--side effects; Contraceptive Usage; Depo-provera--side effects; Developed Countries; Diseases; Family Planning; Injectables--side effects; Levonorgestrel--side effects; Medroxyprogesterone Acetate--side effects; Menstruation Disorders; Metabolic Effects; Method Acceptability; Neoplasms; North America; Northern America; Physiology; Research Methodology; Reversibility; Studies